No company is more future-oriented at the moment than SyrhaTech: a Biotech medical device company located in the heart of Europe, which offers its clients its CDMO (Contract Development and Manufacturing Organization) services. With 30 years of experience in the field of Hyaluronic Acid (cross-linked or non-cross-linked) from its founders, SyrhaTech has carved out a comfortable position in hydrogel prefilled syringe manufacturing.
We support our customers according to their needs: from the product design and development phase, to the production of prefilled syringes batches.
Our clients’ products are used in many medical fields: aesthetic dermatology, orthopedics, ophthalmology and many others.
Our funding Goals :
At the end of meetings at SyrhaTech, we often hear this little phrase as a motto: “Look further, aim higher” and this is particularly true at the moment as the company begins its search for international funding to meet its ambitions.
Let’s talk numbers: SyrhaTech is currently seeking additional funding, amounting to serval million euro, in addition to the initial shareholders’ contribution and the already-raised convertible bridge loan for a total of approximately €10 million.
These additional funds will be used to finance the two aspects of our business:
– Research and Development
– Manufacturing
Invest in our laboratory would allow research team to take a significant step forward in developing even more innovative hyaluronic acid-based solutions to meet the ambitious needs of our clients.
Completing the industrial tool with automatic equipment would enable us to increase our production capacity and meet the numerous requests we receive each week.
These improvements to our work tools will allow us to reach the breakeven point planned for 2025.
Market opportunities:
Hyaluronic Acid (H.A.) is the cornerstone of SyrhaTech. It is the main component of the substance that connects cells together (also called extracellular matrix). H.A. is found in a large part of the human tissues, with its highest concentration located in the dermis, the eye and the joints (50% of the total).
Even though its use and the use of its derivatives are widely spread in the cosmetics industry and in the healthcare sector in general, the complexity of its biochemistry still presents significant opportunities for development in the future.
Today, medical products based on Hyaluronic Acid and related injectable biopolymers represent a market of approximately 12 billion dollars:
– Orthopedics: $2 Billion
– Ophthalmology: $4 Billion
– Dermatology: $4 Billion
– Dentistry: $2 Billion
H.A. is subject to continuous innovation through the industry, leading to new applications, formulas, and indications.
The ageing of the population, the high demand for minimally invasive medical procedures, and the increased regulatory requirements for medical devices to ensure their safety are all opportunities for SyrhaTech to showcase its expertise and perfect mastery of H.A.
How to join the adventure:
If you are interested in investing in healthcare in general, in injectable medical devices and in particular in Hyaluronic Acid and its related polymers, then join us.
We combine our strong expertise in developing innovative solutions with a production capacity in the heart of Europe, while also supporting the sustainable development of the European economy
Learn more about our CDMO business:
The two sides of our business model, like the two sides of a coin, complement each other perfectly:
The D of CDMO: for Product Development.
Some of our clients wish to develop innovative products and turn to SyrhaTech for new formulation development. The extensive experience of SyrhaTech’s founders has allowed the creation of a portfolio of formulations with proven performance. This portfolio is the result of the commitment of our R&D teams.
The M in CDMO: for the Manufacturing of products.
Some of our clients are looking for high-quality generic products where the development cost has been amortized, and for this, we give them access to our existing formulation portfolio. Others need a new manufacturer, SyrhaTech offers them the assurance of being able to manufacture their formulation identically, with the batch size that suits them.
The company benefits from the “Swiss quality” culture, by establishing its product development capacity in Switzerland. It also enjoys affordable skilled labor by setting up its manufacturing plant in France, at the heart of the Alps.
An efficient collaboration on both sides of the Franco-Swiss border.
